110 related articles for article (PubMed ID: 28946961)
1. Secondary thrombotic microangiopathy and eculizumab: A reasonable therapeutic option.
Román E; Mendizábal S; Jarque I; de la Rubia J; Sempere A; Morales E; Praga M; Ávila A; Górriz JL
Nefrologia; 2017; 37(5):478-491. PubMed ID: 28946961
[TBL] [Abstract][Full Text] [Related]
2. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
3. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.
Brocklebank V; Kavanagh D
Clin Kidney J; 2017 Oct; 10(5):600-624. PubMed ID: 28980670
[TBL] [Abstract][Full Text] [Related]
4. Eculizumab in the management of drug-induced thrombotic microangiopathy: A scoping review of the literature.
Zafar A; Lim MY; Abou-Ismail MY
Thromb Res; 2023 Apr; 224():73-79. PubMed ID: 36871347
[TBL] [Abstract][Full Text] [Related]
5. Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance.
Ito S; Saito A; Sakurai A; Watanabe K; Karakawa S; Miyamura T; Yokosuka T; Ueki H; Goto H; Yagasaki H; Kinoshita M; Ozeki M; Yokoyama N; Teranishi H
Bone Marrow Transplant; 2024 Mar; 59(3):315-324. PubMed ID: 38102212
[TBL] [Abstract][Full Text] [Related]
6. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.
Harder MJ; Kuhn N; Schrezenmeier H; Höchsmann B; von Zabern I; Weinstock C; Simmet T; Ricklin D; Lambris JD; Skerra A; Anliker M; Schmidt CQ
Blood; 2017 Feb; 129(8):970-980. PubMed ID: 28028023
[TBL] [Abstract][Full Text] [Related]
7. A Case Report of Quinine-Induced Thrombotic Microangiopathy Successfully Treated With Eculizumab.
Ng JY; Lenton D; Kerridge I; Wong C
J Investig Med High Impact Case Rep; 2024; 12():23247096241235617. PubMed ID: 38477293
[TBL] [Abstract][Full Text] [Related]
8. Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease.
Chonat S; Graciaa S; Shin HS; Newton JG; Quarmyne MO; Boudreaux J; Tang A; Zerra PE; Rollins MR; Josephson CD; Brown C; Joiner CH; Fasano RM; Stowell SR
Haematologica; 2020 Dec; 105(12):2887-2891. PubMed ID: 33256394
[No Abstract] [Full Text] [Related]
9. Chemotherapy-Associated Thrombotic Microangiopathy.
Aklilu AM; Shirali AC
Kidney360; 2023 Mar; 4(3):409-422. PubMed ID: 36706238
[TBL] [Abstract][Full Text] [Related]
10. A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA.
Jodele S; Dandoy CE; Aguayo-Hiraldo P; Lane A; Teusink-Cross A; Sabulski A; Mizuno K; Laskin BL; Freedman J; Davies SM
Blood; 2024 Mar; 143(12):1112-1123. PubMed ID: 37946262
[TBL] [Abstract][Full Text] [Related]
11. C5 inhibition with eculizumab prevents thrombotic microangiopathy in a case series of pig-to-human kidney xenotransplantation.
Jones-Carr ME; Fatima H; Kumar V; Anderson DJ; Houp J; Perry JC; Baker GA; McManus L; Shunk AJ; Porrett PM; Locke JE
J Clin Invest; 2024 Jan; 134(5):. PubMed ID: 38269581
[No Abstract] [Full Text] [Related]
12. Studying the Role of C5-Inhibition Therapy in Scleroderma Renal Crisis-Induced Thrombotic Microangiopathy - A Review of Literature.
Farrukh L; Steen VD; Shapiro L; Mehta S
Semin Arthritis Rheum; 2023 Dec; 63():152256. PubMed ID: 37689027
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy.
Boudhabhay I; Rabant M; Roumenina LT; Coupry LM; Poillerat V; Marchal A; Frémeaux-Bacchi V; El Karoui K; Monchi M; Pourcine F
Front Immunol; 2021; 12():680567. PubMed ID: 34248962
[TBL] [Abstract][Full Text] [Related]
14. MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab.
Elhadad S; Chapin J; Copertino D; Van Besien K; Ahamed J; Laurence J
Clin Exp Immunol; 2021 Jan; 203(1):96-104. PubMed ID: 32681658
[TBL] [Abstract][Full Text] [Related]
15. Eculizumab was safe and effective in the management of transplant-associated thrombotic microangiopathy in a heart transplant recipient with concurrent COVID-19 infection.
Xu C; Wong V; Kurniawan A; Wilson S; Gopal B; Lawton PD
Intern Med J; 2023 Aug; 53(8):1506-1508. PubMed ID: 37599228
[No Abstract] [Full Text] [Related]
16. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy.
Aigner C; Schmidt A; Gaggl M; Sunder-Plassmann G
Clin Kidney J; 2019 Jun; 12(3):333-337. PubMed ID: 31198225
[TBL] [Abstract][Full Text] [Related]
17. Adopting Model-Informed Precision-Dosing for Eculizumab in Transplant Associated-Thrombotic Microangiopathy to Gene Therapies.
Jodele S; Mizuno K; Sabulski A; Vinks AA
Clin Pharmacol Ther; 2023 Sep; 114(3):511-514. PubMed ID: 37387481
[No Abstract] [Full Text] [Related]
18. Severe proteinuria (but not being on dialysis) may be associated with initial inadequate complement inhibition and delayed hematological response to eculizumab therapy.
Allinovi M; Mazzierli T; Caroti L; Antognoli G; Cirami CL
J Nephrol; 2024 Jan; 37(1):253-256. PubMed ID: 38133742
[No Abstract] [Full Text] [Related]
19. Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species.
Zelek WM; Taylor PR; Morgan BP
Immunology; 2019 Aug; 157(4):283-295. PubMed ID: 31120547
[TBL] [Abstract][Full Text] [Related]
20. The role of complement inhibitors in thrombotic microangiopathy with systemic lupus erythematosus.
Memon AA; Lentine KL; Brink D; Said M
Clin Nephrol; 2024 May; 101(5):257-259. PubMed ID: 38431825
[No Abstract] [Full Text] [Related]
[Next] [New Search]
